CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 40 enrolled
Drug / intervention
cAd3-EBO S vaccinebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04041570
NCT04041570Phase 1Completed
CompareCT.gov

A Phase I Open-Label, Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of Two Doses of an Ebola Sudan Chimpanzee Adenovirus Vector Vaccine, VRC-EBOADC086-00-VP (cAd3-EBO S), in Healthy Adults

National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Aug 1, 2019·Updated Dec 6, 2022

In Brief

A Phase 1 clinical trial evaluating cAd3-EBO S vaccine for Ebola Virus. Completed, enrolled 40 participants across 1 site.

Detailed Summary

RV 508 was a Phase I, open-label, dose-escalation study to examine the safety, tolerability and immunogenicity of an investigational Ebola vaccine in healthy adults. VRC-EBOADC086-00-VP, a chimpanzee adenovirus serotype 3 vector-based Ebola vaccine, encodes wild type (WT) glycoprotein (GP) from the Sudan strain of Ebolavirus and is administered intramuscularly (IM).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEbola Virus
CountriesUganda
CollaboratorsUS Military HIV Research Program

Timeline

Phase 1CompletedFinished
2020202120222023202420252026
First PostedAug 1, 2019
Enrollment StartJul 2, 2019
Primary CompletionSep 7, 2020
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 6.9 years ago

Interventions

cAd3-EBO S vaccinebiological

The recombinant chimpanzee adenovirus Type 3-vectored Ebola vaccine, VRC-EBOADC086-00-VP (cAd3-EBO S), is composed of a cAd3 vector that encodes Ebola Sudan wild type glycoprotein (WT GP).